Top 10 AI Healthcare Stocks to Buy

Key Takeaways:

• AI healthcare stocks sit at the intersection of two of the highest-growth themes in global markets: artificial intelligence and healthcare innovation.
• The global AI in the healthcare market is projected to reach USD 50.70 billion in 2026 and surge to over USD 505 billion by 2033 at a 38.9% CAGR.
• CFD traders can gain exposure to these names through MT4 and MT5 without owning the underlying shares.
• With VT Markets, you can trade leading AI medical stocks as CFDs with tight spreads, fast execution, and flexible position sizing.

Why AI Healthcare Stocks Matter for CFD Traders in 2026

AI healthcare stocks sit at the crossroads of two structural megatrends. The first is the global rollout of artificial intelligence in healthcare, which is reshaping how drugs are discovered, how diseases are diagnosed, and how hospitals are run. The second is the steady demand for medical innovation driven by ageing populations across North America, Europe, and Asia Pacific.

The numbers are striking. According to Grand View Research, the global AI in healthcare market was valued at USD 36.67 billion in 2025 and is expected to reach USD 50.70 billion in 2026. By 2033, that figure is projected to climb to USD 505.59 billion, growing at a 38.9% CAGR.

Adoption is keeping pace. The Doximity 2026 State of AI in Medicine Report shows that 63% of US physicians reported using AI in their practice in the November 2025–January 2026 cohort, up from 47% in the March–April 2025 cohort, a 16-point increase across the two study periods.

For CFD traders, these are not just academic figures. Rising adoption translates into rising revenues, which feed directly into share-price movement. That movement is exactly what you can capture through a CFD trading account, without taking ownership of the actual stock.

Trading AI healthcare stocks as CFDs gives you several advantages:

• Two-way exposure: Profit from both rising and falling prices.
• Leverage: Control larger positions with smaller capital outlay.
• No share ownership: No custody fees and no settlement delays.
• 24/5 market access: Trade across US, European, and Asian sessions.
• Hedging flexibility: Offset other positions in your wider portfolio.

This article analyses through the top 10 AI healthcare stocks to buy exposure to in 2026, plus a clear, actionable framework for trading them with a Meta Trader 4 or 5 broker platform.

The Top 10 AI Healthcare Stocks to Buy Exposure to in 2026

The list below blends established large-cap healthcare AI companies with high-growth pure-play innovators. Each one is liquid, widely followed by analysts, and available as a share CFD on most professional MT4 and MT5 platforms.

Below is a closer look at why each name has earned its place on this list.

AI Healthcare Coverage Table: CFRA-Verified Calls vs. Consensus Targets (Apr/May 2026)

Source: CFRA; StockAnalysis; Yahoo Finance; TipRanks

Below are the brief details of the top 10 AI healthcare stocks:

Eli Lilly (LLY)

Eli Lilly is one of the strongest large-cap AI healthcare stocks, combining massive pharmaceutical scale with serious AI investment. In 2025, Lilly partnered with NVIDIA to build an advanced AI supercomputer for drug discovery, manufacturing, medical imaging, and enterprise AI agents.

It also has AI-drug-discovery collaborations with companies such as Genetic Leap and Insilico Medicine. With Q1 2026 revenue up 56% to $19.8 billion, Lilly’s AI strategy is backed by one of the most powerful growth engines in global pharma.

Intuitive Surgical (ISRG)

Intuitive Surgical is a leader in AI-enabled robotic surgery. Its da Vinci 5 system uses AI-powered Case Insights to analyze surgical video, force data, and instrument motion, giving surgeons objective performance feedback.

The company placed 431 da Vinci systems in Q1 2026, including 232 da Vinci 5 units, while revenue rose 23% to $2.77 billion. Intuitive stands out as one of the clearest AI robotics plays in healthcare.

UnitedHealth Group (UNH)

UnitedHealth Group’s AI exposure comes mainly through Optum, its health-services and data analytics arm. In 2025, Optum launched the Optum AI Marketplace to help healthcare organizations deploy vetted AI tools for areas such as prior authorization, payment integrity, and clinical documentation.

UnitedHealth reported Q1 2026 revenue of $111.7 billion, making it a defensive healthcare giant using AI to improve efficiency, automation, and cost management.

Medtronic (MDT)

Medtronic is embedding AI directly into medical devices and surgical systems. Its GI Genius platform uses AI to help detect polyps during colonoscopy, and the company is expanding the platform to support more real-time AI applications.

Medtronic also received expanded FDA clearance for its Stealth AXiS surgical system, which uses AI to generate brain maps for cranial procedures. Q3 FY26 revenue rose 8.7% to $9.02 billion, showing solid momentum behind its AI-enabled device portfolio.

Tempus AI (TEM)

Tempus AI is one of the few public pure-play AI healthcare companies. Its platform uses AI to analyze clinical and molecular data for precision medicine, diagnostics, treatment selection, clinical-trial matching, and drug discovery.

In Q1 2026, revenue rose 36.1% year over year to $348.1 million, with strong growth from both diagnostics and data applications. Tempus offers direct AI healthcare exposure, though it remains more volatile than established large-cap healthcare stocks.

GE HealthCare (GEHC)

GE HealthCare uses AI across medical imaging, diagnostics, ultrasound, CT, MR, and enterprise software. Its large installed base gives it a strong position in AI-enabled diagnostics, where software can improve workflow, image interpretation, and hospital efficiency.

In Q1 2026, revenue rose 7.4% to $5.1 billion, and the company agreed to acquire Intelerad for $2.3 billion to expand its enterprise imaging software business.

Regeneron Pharmaceuticals (REGN)

Regeneron uses AI and machine learning to support genomics, target discovery, trial optimization, and precision medicine. Its collaboration with Viz.ai, Sanofi, and Regeneron applies AI and natural-language processing to electronic health records to improve COPD care.

Q1 2026 revenue increased 19% to $3.6 billion, giving investors exposure to a profitable biotech platform where AI acts as a research and data-analysis accelerator.

Johnson & Johnson (JNJ)

Johnson & Johnson offers diversified AI healthcare exposure through robotic surgery, medical technology, and pharmaceutical R&D. Its OTTAVA robotic surgery system was submitted to the FDA in early 2026, and the company continues to build AI and digital tools across its MedTech pipeline.

Q1 2026 sales rose 9.9% to $24.1 billion. J&J is not a pure AI stock, but it provides a more defensive way to gain exposure to AI’s role in healthcare innovation.

Pfizer (PFE)

Pfizer uses AI mainly to improve drug discovery and development productivity. In 2026, Pfizer partnered with Boltz to develop biomolecular AI foundation models for small-molecule and biologics design. The company is also using its large internal datasets across molecules, clinical trials, and translational research to improve R&D decisions.

Pfizer reported Q1 2026 revenue of $14.5 billion, making it more of a value-oriented pharma turnaround with AI as a long-term productivity lever.

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals is a speculative AI-native drug discovery company. Its platform is built on more than 50 petabytes of proprietary biological and chemical data, allowing it to virtually test drug candidates and support partnerships with major pharma companies such as Sanofi and Roche.

Recursion closed its full financial year 2025 with $753.9M in cash and a runway extending into early 2028 with no additional financing required. Full-year revenue rose to $74.7M (from $58.8M), with Q4 alone contributing $35.5M, lifted by a $30M Roche/Genentech milestone for its second Phenomap. It offers high-risk, high-upside exposure to AI-driven biotech.

Note: This is general information only and not financial advice. For personal guidance, please talk to a licensed professional.

How to Trade AI Healthcare Stocks as CFDs on MT4 and MT5

A CFD, or contract for difference, lets you speculate on the price movement of a stock without owning the underlying share. With a Meta Trader 4 or 5 broker platform such as VT Markets, you can trade these AI healthcare stocks alongside forex, indices, commodities, and crypto from a single account.

Here is a structured workflow that experienced traders typically follow:

• Step 1 — Open a live trading account with a regulated MT4 or MT5 broker.
• Step 2 — Verify your identity and complete the deposit.
• Step 3 — Download MT4 or MT5 on desktop, web, or mobile.
• Step 4 — Search for the share CFD by ticker (for example, #LLY or #ISRG).
• Step 5 — Set your trade size, stop loss, and take profit.
• Step 6 — Monitor and adjust as price action develops.

Sample Calculation: A CFD Trade on Eli Lilly

Let’s walk through a simple example so the mechanics are crystal clear.

Suppose Eli Lilly (LLY) is trading at USD 800 per share. You expect upside following an earnings beat and decide to buy 10 share CFDs with 1:5 leverage.

If the stock rises to USD 850, your profit is (850 − 800) × 10 = USD 500. If it falls to your stop at USD 780, your loss is capped at USD 200. The risk-reward profile is 1:2.5, well above the 1:2 minimum that most professional traders target.

Pro Tips for Trading AI Healthcare Stocks

Apply these habits to lift your edge:

• Risk no more than 1-2% of account equity per trade, regardless of how strong the setup looks.
• Always use a stop loss, share CFDs can gap on earnings, FDA decisions, or trial readouts.
• Trade in the direction of the higher-timeframe trend by checking the daily and weekly charts before entering.
• Avoid holding through binary events like Phase 3 trial readouts unless your strategy is built around them.
• Track sector ETFs such as EDOC and HEAL for broader AI-driven healthcare sentiment.
• Combining fundamentals with price action for a strong earnings beat, plus a clean technical breakout is higher-probability than either signal alone.

Position Sizing: How Much Should You Risk?

A common mistake among new CFD traders is to over-leverage. The table below shows a disciplined risk framework based on a USD 5,000 account.

Notice how a 5% risk per trade, which looks small in isolation, leads to a 12.5-CFD position. Five consecutive losing trades at 5% would cut your account by roughly 23%. At 1%, the same losing streak costs only around 5%, leaving you plenty of capital to recover.

Risks and Catalysts to Watch in 2026

Even the best AI healthcare stocks can move sharply in either direction. The most common catalysts include:

• Clinical trial outcomes, particularly Phase 2 and Phase 3 readouts.
• FDA decisions on new drug approvals or AI-enabled medical devices.
• Quarterly earnings, with a focus on revenue growth and forward guidance.
• Regulatory shifts, such as new EU AI Act provisions affecting medical software.
• Strategic partnerships, including deals with NVIDIA, OpenAI, or hyperscale cloud providers.
• Sector rotation, when capital flows between defensive healthcare and high-beta tech themes.

Key risks worth flagging:

• High R&D costs that may not translate into approved products.
• Reliance on regulatory clearance for AI-enabled medical devices.
• Algorithmic bias and reproducibility issues that can trigger regulatory pushback.
• Concentration risk in many AI healthcare gains in 2025 came from a handful of names.

Why MT4 and MT5 Suit AI Healthcare Stock Traders

Both Meta Trader 4 and Meta Trader 5 give CFD traders access to a deep set of professional tools. MT5 in particular adds an economic calendar, more timeframes, and depth-of-market data, which matter when you are trading event-driven names such as AI medical stocks.

Useful platform features include:

• One-click execution for fast entries and exits around earnings.
• Custom indicators to overlay relative strength versus the S&P 500 HealthCare index.
• Expert Advisors for semi-automated risk management.
• Multi-device sync so you can monitor positions from desktop, web, and mobile.
• Tight spreads on major share CFDs through ECN-style execution.

Frequently Asked Questions (FAQs)

Q1: What are AI healthcare stocks?

AI healthcare stocks are publicly listed companies that use artificial intelligence to improve drug discovery, diagnostics, medical imaging, robotic surgery, or healthcare administration. Examples include Eli Lilly, Intuitive Surgical, Tempus AI, and UnitedHealth Group.

Q2: Can I trade AI healthcare stocks as CFDs?

Yes. Most regulated MT4 and MT5 brokers, including VT Markets, offer share CFDs on the leading AI healthcare names. You speculate on price movement without owning the actual shares, and you can go long or short.

Q3: How much capital do I need to start?

It depends on the broker, the leverage offered, and the share you trade. Many traders begin with USD 500 to USD 2,000, applying strict 1-2% risk per trade. Smaller account types such as cent accounts can also help beginners build experience before scaling up.

Q4: What is the biggest risk with AI healthcare stocks?

Event risk. A single negative trial result or unfavourable FDA decision can trigger a 10-30% gap on the open. Always use a stop loss, avoid oversized positions, and treat earnings dates and clinical readouts with caution.

Q5: How are AI healthcare stocks different from pure AI stocks?

Pure AI stocks such as NVIDIA derive most of their revenue from AI infrastructure. AI healthcare stocks apply AI as a tool inside drug discovery, diagnostics, or hospital operations. They tend to be more defensive and less directly tied to AI capex cycles.

Start Online CFD Trading with VT Markets Today

If you are ready to explore online trading, VT Markets provides access to tools and platforms to help you get started. Trade on powerful platforms like MetaTrader 4 (MT4) and MetaTrader 5 (MT5), designed for speed, reliability, and advanced trading features.

New to trading? You can practise risk-free with a VT Markets demo account before moving to a live CFD account. For ongoing support, our Help Centre offers educational resources and platform guidance to help you build confidence as you learn.

Open your account with VT Markets today and access secure, transparent, and competitive CFD trading across some of the world’s most popular markets.